Table 2.

Cabozantinib related adverse events [21, 34, 83]

Frequent AEs (>50%)	All grades (%)	G3 (%)	Common AEs (50-10%)	All grades (%)	G3 (%)	Not common AEs (<10%)	All grades (%)	G3 (%)
Cardiovascular
hypertension	33–53	8.4–20				pulmonary embolism	3.3	0
Dermatological
palmar-plantar erythrodyesthesia	40–53	13–12	rash	19.2–23	0.9
mucositis	20–53	0–3.3	dry skin	19.2–20.1	0–2.8
Gastrointestinal
diarrhoea	52–87	7.3–21	dysgeusia	26–45	0.1–0.5
decreased appetite	49–80	7–13	constipation	26–34	0-1
nausea	43–80	0–6.9	stomatitis	19–30	1.4–2.6
vomiting	24–60	2.3–7
Constitutional
fatigue	41–80	7–13	arthralgia	14	2.3
weight decrease	35–73	3.4–13	myalgia	7–27	1
			insomnia	10.7	0
			pruritus	13.6	0.5
			headache	13–18.2	0.4–0.5
			alopecia	16.4	0
			hair colour changes	33–34	0.5
Renal
			proteinuria	47	7
Lab alteration
incresed AST	10–100	7–3.2	hypophosphatemia	20	13	increased ALP	3	0
increased ALT	24–73	7-5	hyponatremia	13–33	7–27
increased LDH	73	7
hypocalcemia	23–60	13-0
hypokalemia	47	13-3.8
Haematologic
			anaemia	20–31	7
			leukopenia	27	7
Respiratory tract
			pneumonia	4.2–13	13
			dyspnoea	13.6–21	2.3–3.5
			dysphonia	21–27	0–10.1
Thyroid
			thyroid disfunction	14	0

AE Adverse Event, AST Aspartate Aminotransferase, ALT Alanine Aminotransferase, LDH Lactate Dehydrogenase, ALP Alkaline Phosphatase